Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that HIV, hepatitis C, and hepatitis B are the most important viral infections for drug developers. According to a new Spectrum report entitled Emerging Antiviral Drug Targets, large patient populations, high medical need, and the potential for chronic treatment make these drug markets lucrative for the biopharmaceutical industry.

Among these three infectious diseases, HIV has yielded the highest number of viable drug targets and candidates, partly because of the high level of investment in HIV research and the availability of predictive in vitro models for drug testing.

"Hepatitis C drug development has been hampered by the lack of reliable cell culture systems and animal infection models, but several promising targets, including protease and polymerase, have yielded drug candidates that could potentially revolutionize the treatment of hepatitis C," says John Lebbos, therapeutic area director of infectious diseases at Decision Resources, Inc. "In contrast to HIV and hepatitis C, which have a more diverse array of approaches in advanced stages of development, hepatitis B virus drug development is relatively concentrated within nucleoside analogues."

About Spectrum from Decision Resources

Spectrum is an executive advisory service that identifies and analyzes key business and technology drivers of the pharmaceutical and biotechnology markets. Available only through Decision Resources, Spectrum is a mix of publications and telephone inquiry access to analysts that provides an "over the horizon" perspective on complex health care issues.

About Decision Resources

Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
emarshall@dresources.com

Statins Will Remain the Dominant Class in Treatment of Coronary Heart Disease, Although Their Market Share Will Decline More Than 20%

View Now